zanzalintinib   Click here for help

GtoPdb Ligand ID: 12093

Synonyms: CL-092 | compound 8 [WO2019148044A1] [1] | XL-092 | XL092
Compound class: Synthetic organic
Comment: We obtained the chemical structure for zanzalintinib from the WHO's proposed INN list 127 (21 July 2022). In this document it was described as a tyrosine kinase inhibitor and antineoplastic. The synonym list in PubChem's record for this compound suggests that zanzalintinib is the INN for Exelixis's clinical lead XL092 which is an analogue of cabozantinib [3]. XL092 is an ATP-competitive inhibitor of multiple RTKs including MET, VEGFR2, AXL and MER [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 11
Topological polar surface area 118.65
Molecular weight 528.18
XLogP 4.34
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CNC(=O)c1cc2c(ccnc2cc1OC)Oc1ccc(cc1)NC(=O)C1(CC1)C(=O)Nc1ccc(cc1)F
Isomeric SMILES Fc1ccc(cc1)NC(=O)C1(CC1)C(=O)Nc1ccc(cc1)Oc1ccnc2cc(c(cc12)C(=O)NC)OC
InChI InChI=1S/C29H25FN4O5/c1-31-26(35)22-15-21-23(16-25(22)38-2)32-14-11-24(21)39-20-9-7-19(8-10-20)34-28(37)29(12-13-29)27(36)33-18-5-3-17(30)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,35)(H,33,36)(H,34,37)
1. Bannen LC, Bui M, Jiang F, Tso K, Wang Y, Xu W. (2019)
Compounds for the treatment of kinase-dependent disorders.
Patent number: WO2019148044A1. Assignee: Exelixis, Inc.. Priority date: 26/01/2018. Publication date: 01/08/2019.
2. Hsu J, Chong C, Goon L, Balayan J, Wu S, Johnson E, Lorenzana G, Bannen L, Nguyen L, Scheffold C et al.. (2021)
33 Poster Discussion - XL092, a multi-targeted inhibitor of MET, VEGFR2, AXL and MER with an optimized pharmacokinetic profile.
European Journal of Cancer, 138: S16. DOI: 10.1016/S0959-8049(20)31107-2
3. Yuan L, Li J, Feng M, Zou XR. (2021)
Identification of the metabolites of XL092 in rat and human by using ultra-high performance liquid chromatography high resolution mass spectrometry.
J Pharm Biomed Anal, 206: 114390. [PMID:34600174]